← Eichor
Study identifier: NCT06397560 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial

Condition: Glioma · Glioma, Malignant · Recurrent Glioma  ·  Sponsor: Baptist Health South Florida

PhaseNA
Planned participants28
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this research study is to see if a specific type of radiation therapy, called "proton pulsed reduced dose rate" or "PRDR radiotherapy" has any benefits at dose levels and number of fractions thought to be acceptable in earlier research studies. The researchers want to find out what effects (good and bad) PRDR has on people with cancer in the brain called a "recurrent high-grade glioma" meaning that it grows fast, can spread quickly, and it has come back or gotten worse after being treated previously.

This description comes directly from the study's public registry record.

Talk to the study team

Robert Press, M.D.  ·  (786) 596-2000  ·  Robert.Press@baptisthealth.net

Kristy Reyes  ·  (786) 596-2000  ·  Kristina.Reyes@baptisthealth.net

Always discuss trial participation with your own doctor first.

Locations (2)

Lynn Cancer Institute at Baptist Health, Inc.Boca Raton, Florida, United StatesNot Yet Recruiting
Miami Cancer Institute at Baptist Health, Inc.Miami, Florida, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06397560